Xilis

Founded in 2019 and based in Durham, North Carolina, Xilis is a private, platform-based company focused on revolutionizing oncology drug development. Its core innovation is the MOS Platform, an end-to-end system that automates the creation of patient-derived organoids and uses AI-powered analytics to predict drug efficacy. Xilis partners with biopharma companies and clinicians, providing a service-based model to inform drug discovery, clinical trial design, and patient stratification, positioning itself as a key enabler in the shift towards functional precision medicine.

The MOS (MicroOrganoSphere) Platform: an end-to-end system featuring automated organoid generation (MOSgen device), advanced functional assays, and AI-powered analytics to test drug efficacy on 3D patient-derived models that preserve tumor microenvironment.

Xilis competes in the rapidly evolving field of patient-derived models and organoid services. Competitors range from specialized startups (e.g., Crown Bioscience, Champions Oncology) to large CROs (e.g., Charles River Labs, Labcorp) developing similar offerings. Differentiation hinges on Xilis's automation (MOSgen), speed (4-day assay), and integrated AI analytics.